s6y

Statera Biopharma, Inc.

CIK
1318641
Industry
Pharmaceutical Preparations
Formerly
Cytocom, Inc., CLEVELAND BIOLABS INC

Financials 65

  1. 10-Q Quarterly Report for period ending Sep 30, 2022
  2. 10-Q Quarterly Report for period ending Jun 30, 2022
  3. 10-Q Quarterly Report for period ending Mar 31, 2022
  4. 10-K Annual Report for period ending Dec 31, 2021
  5. NT 10-K Notice under Rule 12b25 of inability to timely file all or part of a Form 10-K, 10-KSB, or 10-KT for period ending Dec 31, 2021
  6. 10-Q Quarterly Report for period ending Sep 30, 2021
  7. 10-Q Quarterly Report for period ending Jun 30, 2021
  8. 10-Q Quarterly Report for period ending Mar 31, 2021
  9. 10-K Annual Report for period ending Dec 31, 2020
  10. 10-Q Quarterly Report for period ending Sep 30, 2020

All 65 financials filings

News 197

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K/A Current report filing
  10. 8-K Current report filing

All 197 news filings

Ownership 263

  1. 3 Initial statement of beneficial ownership of securities
  2. SC 13G/A Major Shareholders
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 3 Initial statement of beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 263 ownership filings

Prospectus 95

  1. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  2. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-4/A Registration of securities issued in business combination transactions
  8. S-4/A Registration of securities issued in business combination transactions
  9. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  10. 425 Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

All 95 prospectus filings

Proxies 33

  1. DEFR14A Definitive revised proxy soliciting materials
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  6. DEF 14A Definitive proxy statements
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.

All 33 proxies filings

Other 111

  1. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  2. 8-A12G Form for registration of a class of securities pursuant to Section 12(g)
  3. D Exempt (Private) Offering
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. UPLOAD Letter (PDF)
  8. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  9. UPLOAD Letter (PDF)
  10. D Exempt (Private) Offering

All 111 other filings